Trial | NCT00235482  Report issue

Official Title

Intratumoural Administration of Coxsackievirus A21 for the Control of Malignant Melanoma (PXS-X02)

  • Phase

    Phase 1

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Study Participants

    3
The purpose of this study is to determine the safety of an injection of coxsackievirus A21 into a melanoma tumour, and also to see if there is a tumour response.
Coxsackievirus A21, a naturally occurring enterovirus, has shown that in vivo it can infect and lyse melanoma. This study is to assess safety of a single intratumoural injection of the virus into an accessible subcutaneous melanoma metastasis.
Study Started
Nov 08
2005
Primary Completion
Apr 21
2006
Study Completion
Apr 21
2006
Last Update
Jun 27
2019

Drug Coxsackievirus A21

Criteria 

Inclusion Criteria:

stage IV melanoma (AJCC classification)
minimum of 2 sc metastases
failure or refusal of standard chemotherapy
ECOG score of 0 or 1
other

Exclusion Criteria:

metastatic CNS disease
ocular or mucosal melanoma
immunodeficiency
splenectomy
other
No Results Posted